High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
0 drugs in development·0 companies·2 clinical trials
Frequently asked questions
How many clinical trials target High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements?
There are 2 clinical trials targeting High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements tracked by BioSniper.
What is the prevalence of High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements?
The estimated prevalence of High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements is approximately 56.0 per 100,000 population.
Deep-dive into High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis